A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia

NeuroBo Pharmaceuticals Inc.91 enrolled

Overview

A 12-Week, Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects with Severe Hypertriglyceridemia (INDIGO-1)

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

TRIPLE

Enrollment

Conditions

Severe Hypertriglyceridemia Mixed Dyslipidaemia

Interventions

GemcabeneDRUG

Gemcabene tablets administered orally once daily, for 12 weeks.

PlaceboDRUG

Placebo tablets administered orally once daily, for 12 weeks.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: Subjects who meet all of the following criteria will be eligible to participate in the study: 1. Provision of written and signed informed consent (by subject or legal guardian) prior to any study-specific procedure; 2. Male or female (neither pregnant or lactating) ≥18 years of age at time of consent; 1. Women of child-bearing potential must have a negative serum pregnancy test at the Screening Visit and negative urine dipstick on Study Day 1 prior to dosing in order to qualify for the study. Women who are surgically sterile or are clinically confirmed to be post-menopausal (i.e., documented amenorrhea for ≥ 1 year in the absence of other biological or physiological causes) are not considered to be of child-bearing potential; 2. Women of child-bearing potential must agree to use acceptable methods of contraception throughout the duration of the study and for 30 days after the last dose of study drug. For this study, double-barrier contraception is required. 3. Currently on a self-reported, stable, low-fat, low-cholesterol diet in combination with stable statins with or without ezetimibe (10 mg QD) for at least 12 weeks prior to the Screening Visit; 4. Mean fasting TG value ≥ 500 mg/dL to \< 1500 mg/dL (with the higher value no more than 50% greater than the lower value) from the S1 and S2 Visits (or alternatively S2 and S3); 5. Physical examination, including vital signs, that is within normal limits or clinically acceptable to the Investigator; 6. Weight ≥ 50 kg; with a body mass index (BMI) ≤ 45 kg/m²; and 7. Subjects with Type 2 diabetes who take anti-diabetes pharmacologic therapy must be on a stable a regimen for at least 3 months, with no planned changes in medications for the study duration. Exclusion Criteria: Subjects who meet any of the following criteria will be excluded from participation in the study: 1. Known and previously documented homozygous genetic deficiencies (LPL, ApoC-II, ApoC-III, ApoA-V, GPIHBP1, or LMF1); 2. History of pancreatitis within the last 6 months prior to screening (Visit S1); 3. History of bariatric surgery; symptomatic gallstone disease, unless treated with cholecystectomy; 4. Abnormal liver function test at the Pre-Screening Visit or any of the Screening Visits (aspartate aminotransferase or alanine aminotransferase \> 2 × the upper limit of normal \[ULN\], total bilirubin \> 1.5 × ULN, or alkaline phosphatase \> 2 × ULN based on appropriate age and gender normal values). Subjects with bilirubin \> 1.5 × ULN and history of Gilbert's syndrome may be included; reflexive direct bilirubin testing will be used to confirm Gilbert's syndrome; 5. Active liver disease (e.g., cirrhosis, alcoholic liver disease, hepatitis B \[HBV\], hepatitis C \[HCV\], autoimmune hepatitis, liver failure, liver cancer), history of liver transplant, known diagnosis of human immunodeficiency virus (HIV), or acquired immune deficiency virus; 6. Moderate to severe renal insufficiency defined as an estimated GFR \< 60 mL/min/1.73 m2 (calculated using The Chronic Kidney Disease Epidemiology Collaboration equation) at the Pre-Screening Visit or at any of the Screening Visits; 7. Abnormal urinalysis (proteinuria greater than trace or any male or non-menstruating female with greater than trace hematuria), confirmed by reflexive urine protein:creatinine ratio testing; 8. Uncontrolled thyroid disease: hyperthyroidism or hypothyroidism as defined by thyroid stimulating hormone (TSH) below the lower limit of normal or \> 1.5 × ULN, respectively, based on results from the Pre-Screening Visit or the Screening Visit. If controlled, treatment should be stable for at least 3 months prior to the Screening Visit; 9. Type 1 diabetes mellitus or uncontrolled type 2 diabetes mellitus HbA1c value ≥8.5% based on results from the Pre-Screening Visit or the Screening Visit), or any diabetic subject taking a thiazolidinedione (e.g., pioglitazone, rosiglitazone); 10. New York Heart Association Class III or IV heart failure (see Appendix C); 11. Myocardial infarction, severe or unstable angina pectoris, coronary angioplasty, coronary artery bypass graft, or other major cardiovascular events resulting in hospitalization within 3 months of the Screening Visit (S1). Subjects with adequately treated stable angina, per Investigator assessment, may be included; 12. Uncontrolled cardiac arrhythmia or prolonged QT on the Screening Visit or Study Day 1 prior to dosing ECG (QTcF \> 450 msec for men and \>470 msec for women) or known family history of prolonged QT or unexplained sudden cardiac death; 13. Uncontrolled hypertension, defined as sitting systolic blood pressure ≥ 180 mmHg or diastolic blood pressure ≥ 110 mmHg, and confirmed by repeat measurement; 14. Currently receiving cancer treatment(s) or, in the Investigator's opinion, at risk of relapse for recent cancer; 15. Inadequate washout of a PCSK9 inhibitor (8 weeks prior to the Screening Visit S1), a fibrate lipid lowering agent (6 weeks prior to the Screening Visit S1), niacin \> 200 mg/day, OMG-3, bile acid sequestrants or other lipid lowering therapies (4 weeks prior to the Screening Visit S1); 16. Use of any excluded medications or supplements within 3 months prior to S1 (e.g., potent cytochrome P450 \[CYP\] 3A4 inhibitors, see Appendix D); 17. Hypersensitivity to or a history of significant adverse reactions to any fibrate lipid regulating agent; 18. History of drug or alcohol abuse within the past year or inability to comply with protocol requirements, including subject alcohol restrictions (see Section 5.6.3); 19. Previously treated with gemcabene (i.e., CI-1027); participation in another clinical study of an investigational agent or device concurrently or within 1 month prior to the Screening Visit, or use of an investigational agent within 1 month or 5 half-lives (if known), whichever is longer, prior to the Screening Visit; or 20. Any other finding which, in the opinion of the Investigator, would compromise the subject's safety or participation in the study.

Locations (49)

Outcomes

Primary Outcomes

Percent Change From Baseline to End of Study (EOS) in Fasting Serum Triglycerides (TG)

EOS was defined as the average of the week 10 and week 12 values. If either the week 10 or week 12 value was missing, then the single value (week 10 or week 12) was used. Completely missing values (both week 10 and week 12) were imputed using last observation carried forward (LOCF).

Time frame: Baseline, EOS (average of week 10 and 12)

Secondary Outcomes

Percent Change From Baseline in Fasting Serum TG

Time frame: Baseline, Weeks 2, 6, 10 and 12

Change From Baseline in Fasting Serum TG

Time frame: Baseline, Weeks 2, 6, 10, 12 and EOS (average of week 10 and 12)

Percent Change From Baseline in TC

Time frame: Baseline, Weeks 2, 6, 10, 12 and EOS (average of week 10 and 12)

Change From Baseline in TC

Time frame: Baseline, Weeks 2, 6, 10, 12 and EOS (average of week 10 and 12)

Percent Change From Baseline in Non-HDL-C

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Appalachian Research Associates

Fort Payne, Alabama, United States

Del Sol Research Mangagement, LLC

Tucson, Arizona, United States

Westside Medical Associates of Los Angeles

Beverly Hills, California, United States

Hope Clinical Research

Canoga Park, California, United States

SC Clinical Research

Garden Grove, California, United States

National Research Institute

Huntington Park, California, United States

National Research Institute

Los Angeles, California, United States

Paradigm Clinical Research

San Diego, California, United States

Paradigm Research

Wheat Ridge, Colorado, United States

Excel Medical Research

Boca Raton, Florida, United States

...and 39 more locations

Time frame: Baseline, Weeks 2, 6, 10, 12 and EOS (average of week 10 and 12)

Change From Baseline in Non-HDL-C

Time frame: Baseline, Weeks 2, 6, 10, 12 and EOS (average of week 10 and 12)

Percent Change From Baseline in VLDL-C

Time frame: Baseline, Weeks 2, 6, 10, 12 and EOS (average of week 10 and 12)

Change From Baseline in VLDL-C

Time frame: Baseline, Weeks 2, 6, 10, 12 and EOS (average of week 10 and 12)

Percent Change From Baseline in HDL-C

Time frame: Baseline, Weeks 2, 6, 10, 12 and EOS (average of week 10 and 12)

Change From Baseline in HDL-C

Time frame: Baseline, Weeks 2, 6, 10, 12 and EOS (average of week 10 and 12)

Percent Change From Baseline in Apolipoprotein B

Time frame: Baseline, Weeks 10, 12 and EOS (average of week 10 and 12)

Change From Baseline in Apolipoprotein B

Time frame: Baseline, Weeks 10, 12 and EOS (average of week 10 and 12)

Percent Change From Baseline in Apolipoprotein A-I

Time frame: Baseline, Weeks 10, 12 and EOS (average of week 10 and 12)

Change From Baseline in Apolipoprotein A-I

Time frame: Baseline, Weeks 10, 12 and EOS (average of week 10 and 12)

Percent Change From Baseline in Apolipoprotein A-II

Time frame: Baseline, Weeks 10, 12 and EOS (average of week 10 and 12)

Change From Baseline in Apolipoprotein A-II

Time frame: Baseline, Weeks 10, 12 and EOS (average of week 10 and 12)

Percent Change From Baseline in Apolipoprotein C-II

Time frame: Baseline, Weeks 10, 12 and EOS (average of week 10 and 12)

Change From Baseline in Apolipoprotein C-II

Time frame: Baseline, Weeks 10, 12 and EOS (average of week 10 and 12)

Percent Change From Baseline in Apolipoprotein C-III

Time frame: Baseline, Weeks 10, 12 and EOS (average of week 10 and 12)

Change From Baseline in Apolipoprotein C-III

Time frame: Baseline, Weeks 10, 12 and EOS (average of week 10 and 12)

Percent Change From Baseline in Apolipoprotein E

Time frame: Baseline, Weeks 10, 12 and EOS (average of week 10 and 12)

Change From Baseline in Apolipoprotein E

Time frame: Baseline, Weeks 10, 12 and EOS (average of week 10 and 12)

Percent Change From Baseline in LDL-C

Time frame: Baseline, Weeks 10, 12 and EOS (average of week 10 and 12)

Change From Baseline in LDL-C

Time frame: Baseline, Weeks 10, 12 and EOS (average of week 10 and 12)

Percent Change From Baseline in LDL-TG

Time frame: Baseline, Weeks 10, 12 and EOS (average of week 10 and 12)

Change From Baseline in LDL-TG

Time frame: Baseline, Weeks 10, 12 and EOS (average of week 10 and 12)

Percent Change From Baseline in VLDL-TG

Time frame: Baseline, Weeks 10, 12 and EOS (average of week 10 and 12)

Change From Baseline in VLDL-TG

Time frame: Baseline, Weeks 10, 12 and EOS (average of week 10 and 12)

Percent Change From Baseline in HDL-TG

Time frame: Baseline, Weeks 10, 12 and EOS (average of week 10 and 12)

Change From Baseline in HDL-TG

Time frame: Baseline, Weeks 10, 12 and EOS (average of week 10 and 12)

Percent Change From Baseline in Lipoprotein Size

Percent change from baseline in Particle size for VLDL, HDL and LDL were reported.

Time frame: Baseline, Week 12

Change From Baseline in Lipoprotein Size

Change from baseline in Particle size for VLDL, HDL and LDL were reported.

Time frame: Baseline, Week 12

Percent Change From Baseline in Lipoprotein Particle Number

Percent change from baseline in particle number for VLDL \& chylomicron, LDL and IDL were reported.

Time frame: Baseline, Week 12

Change From Baseline in Lipoprotein Particle Number

Change from baseline in particle number for VLDL \& chylomicron, LDL and IDL were reported.

Time frame: Baseline, Week 12

Percent Change From Baseline in HDL Particle Number

Time frame: Baseline, Week 12

Change From Baseline in HDL Particle Number

Time frame: Baseline, Week 12

Percent Change From Baseline in High-sensitivity C-reactive Protein

Time frame: Baseline, Weeks 10, 12 and EOS (average of week 10 and 12)

Change From Baseline in High-sensitivity C-reactive Protein

Time frame: Baseline, Weeks 10, 12 and EOS (average of week 10 and 12)

Percent Change From Baseline in Fibrinogen

Time frame: Baseline, Weeks 10, 12 and EOS (average of week 10 and 12)

Change From Baseline in Fibrinogen

Time frame: Baseline, Weeks 10, 12 and EOS (average of week 10 and 12)

Percent Change From Baseline in Serum Amyloid A

Time frame: Baseline, Weeks 10, 12 and EOS (average of week 10 and 12)

Change From Baseline in Serum Amyloid A

Time frame: Baseline, Weeks 10, 12 and EOS (average of week 10 and 12)

Percent Change From Baseline in Adiponectin

Time frame: Baseline, Week 12 and EOS (average of week 10 and 12)

Change From Baseline in Adiponectin

Time frame: Baseline, Week 12 and EOS (average of week 10 and 12)

Percent Change From Baseline in Angiopoietin 4

Time frame: Baseline, Week 12 and EOS (average of week 10 and 12)

Change From Baseline in Angiopoietin 4

Time frame: Baseline, Week 12 and EOS (average of week 10 and 12)

Percent Change From Baseline in Interleukin-6

Time frame: Baseline, Weeks 10, 12 and EOS (average of week 10 and 12)

Change From Baseline in Interleukin-6

Time frame: Baseline, Weeks 10, 12 and EOS (average of week 10 and 12)

Percentage of Participants Achieving a TG Value < 500 mg/dL (5.65 mmol/L)

Time frame: Weeks 10, 12 and EOS (average of week 10 and 12)